I looked at Opyl’s technology back in 2022 and while I think it has real value outside of oncology, the way the oncology clinical trial works here in Australia it is not a good fit for bisantrene.
Industry news, page-1784
-
- There are more pages in this discussion • 608 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.78 |
Change
-0.005(0.28%) |
Mkt cap ! $303.3M | |||
| Open | High | Low | Value | Volume |
| $1.80 | $1.84 | $1.78 | $133.8K | 73.76K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 15072 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 1793 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |